Elixxer Stock Performance
| ELIXF Stock | USD 0.04 0.01 55.70% |
Elixxer holds a performance score of 8 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 13.93, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Elixxer will likely underperform. Use Elixxer total risk alpha and the relationship between the potential upside and price action indicator , to analyze future returns on Elixxer.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Elixxer are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Elixxer reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 2.1 M | |
| Total Cashflows From Investing Activities | 2.2 M | |
| Free Cash Flow | -4 M |
Elixxer |
Elixxer Relative Risk vs. Return Landscape
If you would invest 7.51 in Elixxer on September 28, 2025 and sell it today you would lose (3.96) from holding Elixxer or give up 52.73% of portfolio value over 90 days. Elixxer is currently producing 9.0482% returns and takes up 83.4145% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Elixxer, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Elixxer Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Elixxer's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Elixxer, and traders can use it to determine the average amount a Elixxer's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1085
| Best Portfolio | Best Equity | ELIXF | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Elixxer is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Elixxer by adding it to a well-diversified portfolio.
Elixxer Fundamentals Growth
Elixxer Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Elixxer, and Elixxer fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Elixxer Pink Sheet performance.
| Return On Equity | -3.41 | |||
| Return On Asset | -0.031 | |||
| Operating Margin | (8.81) % | |||
| Current Valuation | 9.36 M | |||
| Shares Outstanding | 11.35 M | |||
| Price To Book | 2.45 X | |||
| Price To Sales | 139.36 X | |||
| EBITDA | (1.94 M) | |||
| Cash And Equivalents | 4.22 M | |||
| Cash Per Share | 0.37 X | |||
| Total Debt | 8.02 M | |||
| Debt To Equity | 1.60 % | |||
| Book Value Per Share | (0.22) X | |||
| Cash Flow From Operations | (4.02 M) | |||
| Earnings Per Share | (0.62) X | |||
| Total Asset | 16.84 M | |||
About Elixxer Performance
By analyzing Elixxer's fundamental ratios, stakeholders can gain valuable insights into Elixxer's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Elixxer has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Elixxer has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Elixxer Ltd. operates as a cannabis investment firm in Canada, Australia, Italy, Jamaica, and Switzerland. Elixxer Ltd. was incorporated in 2004 and is based in Montreal, Canada. Elixxer is traded on OTC Exchange in the United States.Things to note about Elixxer performance evaluation
Checking the ongoing alerts about Elixxer for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Elixxer help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Elixxer is way too risky over 90 days horizon | |
| Elixxer has some characteristics of a very speculative penny stock | |
| Elixxer appears to be risky and price may revert if volatility continues | |
| Elixxer has high likelihood to experience some financial distress in the next 2 years | |
| Elixxer has accumulated 8.02 M in total debt with debt to equity ratio (D/E) of 1.6, which is about average as compared to similar companies. Elixxer has a current ratio of 0.64, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Elixxer until it has trouble settling it off, either with new capital or with free cash flow. So, Elixxer's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Elixxer sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Elixxer to invest in growth at high rates of return. When we think about Elixxer's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (3.66 M) with profit before overhead, payroll, taxes, and interest of 42.41 K. | |
| Elixxer has accumulated about 4.22 M in cash with (4.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.37, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 35.0% of Elixxer shares are held by company insiders |
- Analyzing Elixxer's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Elixxer's stock is overvalued or undervalued compared to its peers.
- Examining Elixxer's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Elixxer's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Elixxer's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Elixxer's pink sheet. These opinions can provide insight into Elixxer's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Elixxer Pink Sheet analysis
When running Elixxer's price analysis, check to measure Elixxer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elixxer is operating at the current time. Most of Elixxer's value examination focuses on studying past and present price action to predict the probability of Elixxer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elixxer's price. Additionally, you may evaluate how the addition of Elixxer to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |